how psilocybin affects those struggling with mental health and trauma. Getting in touch with your emotions.
Over-eating disorders occur when the brain is not providing the patient with a signal to feel full.
According the the Chief Scientific Officer of Tryp Therapeutics (TRYP), psilocybin therapy could be used to correct the malfunctioning neural network while helping patients work through food-related anxiety.
This week, the company got the go-ahead from the FDA to continue its binge eating study, so we’ll soon know if the theory holds true!
Plus, the effects are long-lasting!
A recent analysis found that, on average, patients who received MDMA-assisted therapy experienced a 22 point reduction in PTSD scores, whereas daily antidepressants only reduced scores by 6 to 14 points.
One year after receiving the treatments, patients still reported benefits:
Why is it so effective? MDMA reduces feelings of intense anxiety, allowing patients to open up and work through traumatic memories without fear.
HaluGen Life Sciences expanded its psychedelic DNA test – it can now assess how your body metabolizes LSD, MDMA and ayahuasca.
The kit tests for a CYP2D6 gene mutation, which can cause metabolism of the drugs to take up to twice as long. This could lead to longer, more intense trips and adverse reactions.
Thankfully, the mutation is only present in 5-10% of people!
Evidence suggests that microdosing improves cognitive function and memory. This kit could take the benefits up a notch.👇🏽
Ixtlan Bioscience, a private Israeli company, filed a US patent for a microdosing kit that can be used at home to treat Alzheimer’s, brain damage, and neuronal disorders.
The kit includes:
Who knows, maybe this time next year, it’ll be the trending gift to put under the tree. 🎄
MindMed (MNMD) is collaborating with universities in Switzerland and the Netherlands to study the effects of microdosing LSD on adults with ADHD. Patients will be assessed on symptoms of inattention, impulsivity, and hyperactivity after microdosing twice a week for six weeks.
“The study builds on the growing evidence demonstrating LSD has the potential to improve mood and selective cognitive processes,” says the company’s new CEO, Robert Barrow, who was appointed this week.
Nova Mentis (NOVA) and Mycrodose Therapeutics successfully created a transdermal patch that delivers Nova’s psilocybin formulation through the skin. The companies aim to use the patch to administer microdoses to autistic patients to treat cognitive impairments.
This method could be administered at home to reduce medical costs for families and save time for overworked medical professionals.
Antidepressants are often ineffective and can even interfere with cancer treatment drugs.
“Psychedelics are proving to not conflict with the cancer drug and are more effective than normal antidepressants generally,” according Frank Lane, director of Albert Labs.
That’s why the BC-based company wants to bring a psilocybin treatment for cancer patients to European markets.
Albert Labs is expected to begin trading on the CSE early next year under the ticker ’ABRT’.
COMPASS Pathways’ (CMPS) announced that patients taking SSRI antidepressants in conjunction with psilocybin therapy had similar outcomes and fewer side effects compared to those who withdrew from SSRIs before the study.
Five patients who withdrew from SSRIs had serious adverse effects, such as suicidal ideation, when given the largest dose. None of the patients on SSRIs had this experience.
Dr. Matthew Johnson’s research found that 59% of nicotine-addicted patients remained abstinent from smoking for 12 months after receiving a single macrodose of psilocybin. Only 28% of patients on a nicotine patch remained abstinent for the same time period.
His other research shows that multiple psilocybin doses can have an 80% success rate!
GH Research (GHRS) discovered that the most powerful psychedelic, 5-MeO-DMT (aka toad venom), is highly effective at curing treatment-resistant depression.
Out of eight patients, seven were in remission from depression just one day after receiving the company’s proprietary formulation, and five of those were in remission in as little as two hours.
All eight patients showed improved depression scores, with an average reduction of 76%.
